Back to Search

CHRISTOPHER SOTIRIOU, PHARM.D., MBA

PHARM.D., MBA

Pharmacotherapy Pharmacist

NPI: 1457436461Individual

Specialties, Licenses & Credentials

Pharmacist

Pharmacist

Code: 183500000X

324309-1701(UT)
Pharmacotherapy PharmacistPrimary

Pharmacist — Pharmacotherapy

Code: 1835P1200X

3243091701(UT)

Research & Publications (20)

Gene-expression signatures in breast cancer.
PMID 19228622·N Engl J Med·2009
6-review
Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care?
PMID 17585334·Nat Rev Cancer·2007
6-review
Molecular profiling of head and neck tumors.
PMID 15069314·Curr Opin Oncol·2004
6-review
Breast cancer classification and prognosis based on gene expression profiles from a population-based study.
PMID 12917485·Proc Natl Acad Sci U S A·2003
8-other
Core biopsies can be used to distinguish differences in expression profiling by cDNA microarrays.
PMID 11826185·J Mol Diagn·2002
4-observational
Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer.
PMID 12052255·Breast Cancer Res·2002
4-observational
Interleukins-6 and -11 expression in primary breast cancer and subsequent development of bone metastases.
PMID 11410329·Cancer Lett·2001
8-other
HER-2 as a target for breast cancer therapy.
PMID 19289395·Clin Cancer Res·2009
8-other
Quantitation of HER2 expression or HER2:HER2 dimers and differential survival in a cohort of metastatic breast cancer patients carefully selected for trastuzumab treatment primarily by FISH.
PMID 19214112·Diagn Mol Pathol·2009
8-other
Genomic grade index is associated with response to chemotherapy in patients with breast cancer.
PMID 19364972·J Clin Oncol·2009
8-other
Development and validation of gene expression profile signatures in early-stage breast cancer.
PMID 19191098·Cancer Invest·2009
6-review
Molecular profiling of CD3-CD4+ T cells from patients with the lymphocytic variant of hypereosinophilic syndrome reveals targeting of growth control pathways.
PMID 19608752·Blood·2009
8-other
Better translation from bench to bedside: breakthroughs in the individualized treatment of cancer.
PMID 19104222·Crit Care Med·2009
8-other
Association between farnesoid X receptor expression and cell proliferation in estrogen receptor-positive luminal-like breast cancer from postmenopausal patients.
PMID 18563553·Breast Cancer Res Treat·2009
8-other
The Gene expression Grade Index: a potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 1-98 trial.
PMID 19573224·BMC Med Genomics·2009
8-other
Gene expression profiling identifies activated growth factor signaling in poor prognosis (Luminal-B) estrogen receptor positive breast cancer.
PMID 19552798·BMC Med Genomics·2009
8-other
Absence of ESR1 amplification in a series of breast cancers.
PMID 18816632·Int J Cancer·2008
8-other
Treatment tailoring based on molecular characterizations.
PMID 18790978·Ann Oncol·2008
8-other
Comparison of prognostic gene expression signatures for breast cancer.
PMID 18717985·BMC Genomics·2008
4-observational
Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes.
PMID 18698033·Clin Cancer Res·2008
1-meta

Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.

Contact & Hours

Address
242 E BROADWAY
SALT LAKE CITY, UT 84111

Location

Practice Location

242 E BROADWAY, SALT LAKE CITY, UT
(801) 641-8121

Quick Facts

NPI
1457436461
Entity Type
Individual
Gender
Male
Medicare
Not confirmed
Specialties
2
Locations
1
Publications
20

Are you this provider?

Claim Your Profile